Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?

INTRODUCTION: Siponimod, a potent and selective sphingosine-1-phosphate (S1P(1,5)) agonist, is the only therapeutic agent that has shown efficacy against disability progression, decline in cognitive processing speed, total brain volume loss, gray matter atrophy and signs of demyelination in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Bigaud, Marc, Ramseier, Pamela, Tisserand, Sarah, Lang, Meike, Urban, Beatrice, Beerli, Christian, Karlsson, Göril
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310674/
https://www.ncbi.nlm.nih.gov/pubmed/37195409
http://dx.doi.org/10.1007/s40120-023-00487-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310674/
https://www.ncbi.nlm.nih.gov/pubmed/37195409
http://dx.doi.org/10.1007/s40120-023-00487-4

Ejemplares similares